The bek gene encodes a member of the highaffinity fibroblast growth factor receptor family. The BEK/FGFR-2 receptor is a membrane-snning tyrosine kinase with the typical features ofFGF receptors. We have cloned a murine bek cDNA and expressed it in receptor-negative Chinese hamster ovary cells and in 32D myeloid cells. The BEK receptor expressed in Chinese hamster ovary cells binds acidic FGF, basic FGF, and Kaposi FGF equally well but does not bind keratinocyte growth factor or FGF-5 appreciably. Upon treatment with basic FGF or Kaposi FGF, the BEK receptor is phosphorylated and a mitogenic response is achieved. Heparan sulfate proteoglycans have been shown to play an obligate role in basic FGF binding to the high-affinity FLG receptor. Unlike the BEK-expressing Chinese hamster ovary cells, 32D cells expressing the BEK receptor require the addition of exogenous heparin in order to grow in the presence of basic FGF or Kaposi FGF. We show that the addition of heparin greatly enhances the binding of radio-labeled basic FGF to the receptor. Thus the BEK receptor, like FLG, also requires an interaction with heparan sulfate proteoglycans to facilitate binding to its ligands.
Fibroblast growth factors (FGFs) are a family of seven heparin-binding polypeptides that share 30-40% homology (1) . Like other growth factors, FGFs act by binding and activating specific cell-surface receptors, and the FGF receptors also represent a family of related, but distinct, membrane-spanning tyrosine kinases. Four such FGF receptors have thus far been cloned. These include the FLG receptor or FGFR-1 (2-5), the BEK receptor or FGFR-2 (6-10), FGFR-3 (10, 11) , and, recently, a human FGFR-4 (12) . Related receptors capable of binding bFGF have also been described in Xenopus and Drosophila (13, 14) .
Each of these receptors consists of an extracellular ligand binding region containing three immunoglobulin-like domains (15) and an intracellular split tyrosine kinase domain. The FLG and BEK receptors are most closely related and bind acidic FGF (aFGF) and basic FGF (bFGF) with equal affinities (7, 16) . FGFR-3 has also been shown to bind both growth factors (11) , whereas FGFR-4 binds aFGF but not bFGF (12) , thus providing one example of strict ligand specificity in this receptor family. The FLG receptor binds Kaposi FGF (K-FGF) with -15x lower affinity than aFGF or bFGF (5) .
In addition to multiple receptors for the FGF family, variant forms of FLG and BEK have been described that probably arise from alternative RNA splicing, thereby increasing the complexity of this receptor family (4, 16, 17) . A shorter form of FLG, which is missing the N-terminal, immunoglobulin-like domain, binds with high affinity to aFGF, bFGF, and K-FGF, indicating that the first immunoglobulin-like domain of the receptor is dispensable for ligand binding (5, 16 ). An isoform of BEK, which results from alternative splicing, was cloned from a keratinocyte expression library as a receptor for keratinocyte growth factor (KGF) (17) . It binds aFGF and KGF with high affinity but exhibits very low affinity for bFGF (17) . Adding another dimension to FGF-receptor interaction are the low-affinity FGF receptors or heparan sulfate proteoglycans (HSPGs), which have been shown to play an essential role in the binding of bFGF to FLG (18) and in bFGF-mediated fibroblast growth and myoblast differentiation (19) .
Since the FGFs seem to interact with only partial specificity with a family of receptor tyrosine kinases, which are often coexpressed in the same cells, the question arises of why such a degree of redundancy exists in this system. A first step necessary to answer this question is the precise characterization of each of the FGF receptors, its binding specificity, and the factors required for its activation. In this report we describe the cloning and characterization of a three-immunoglobulin-domain form of murine BEK. This receptor, when expressed in Chinese hamster ovary (CHO) cells, is capable of binding aFGF, bFGF, and K-FGF with equal affinity but does not bind KGF or FGF-5 appreciably. The BEK receptor is phosphorylated in response to the three former factors, and a proliferative response is elicited. When BEK is introduced in the 32D myeloid cell line, which is normally interleukin 3 (IL-3) dependent (20) and does not appear to express high-or low-affinity FGF receptors, the cells can respond to FGFs instead of IL-3, but only in the presence of exogenous heparin. In the presence of heparin, the binding of 1'I-labeled bFGF (125I-bFGF) to the BEK receptor is dramatically enhanced, indicating that this receptor also requires HSPGs to facilitate ligand binding. ¶ MATERIALS AND METHODS Library Screening and Sequencing. A AgtlO cDNA library from A-15 cells was screened using an 800-base-pair (bp) fragment from the tyrosine kinase portion of the partial bek cDNA as a probe (6) . Filters were hybridized as described (5) . The cDNAs were subcloned into pBluescript (Stratagene) and sequenced (21 IThe sequence reported in this paper has been deposited in the GenBank data base (accession no. M86441).
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Cell Lines and Transfections. CHO-DG44 cells were maintained as described (5) . Cells were transfected by calcium phosphate precipitation with a 3.7-kilobase (kb) bek cDNA in p91023B vector (22) . Positive clones were selected in medium lacking hypoxanthine and thymidine (5) . The stably transfected 32D cells were isolated after electroporation with the bek cDNA expressed in the pZip-NeoSV(X)1 vector (23) . For electroporation and selection, 5 x 106 cells were suspended in 1 ml of cold phosphate-buffered saline (PBS) with 50 pug of plasmid DNA in a Gene Pulser cuvette. The cuvette was exposed to a 650-V impulse, 25 ,uF (Gene Pulser, Bio-Rad), and kept on ice for 15 min. The cells were diluted in Iscove's medium with 10% heat-inactivated fetal calf serum and IL-3 (10 units/ml). After 24 hr the cells were put in medium containing geneticin (625 tkg/ml).
Binding Assays. Recombinant bFGF was iodinated as described (24) (specific activity = 552 cpm/fmol). Recombinant K-FGF was iodinated with 125I-labeled Bolton-Hunter reagent. The radioactive K-FGF was repurified on heparinSepharose with 0.15% gelatin added to all buffers and had a specific activity of 63 cpm/fmol. For Scatchard analysis, clone CHO bek 3.7-5 was incubated with various concentrations of 125I-bFGF from 0.25 to 10 ng/ml. Radioactive bFGF bound to high-affinity receptors was quantitated as described (5) . Competition assays were performed as described (5) . Heparin (10 ,g/ml) was included in all assays (24) .
Growth Curves. On day 0, 32D cells were washed with serum-free medium and seeded at 1.5 x 105 cells per ml in Iscove's medium with 10% heat-inactivated fetal calf serum, and various growth factors were added as indicated. Cells were counted in duplicate on days 2, 4, and 6.
Crosslinking to 32D Cells. 125I-bFGF was prepared by mild chloramine-T treatment and purified over a Sephadex G-25 column. The specific activity of 1251-bFGF was 4 x 104cpm/ng (800 cpm/fmol). Cells (5 x 106) were washed twice in ice-cold PBS and resuspended in 0.5 ml of binding medium (Iscove's medium/0.15% gelatin) and 125I-bFGF at 10 ng/ml. Unlabeled bFGF (1 jg/ml) and heparin (10 ,Lg/ml) were included as indicated. The binding was performed for 2 hr at 4°C with gentle agitation of samples. The cells were washed twice in ice-cold PBS and crosslinked with disuccinimidyl suberate (Pierce) (3 mM in PBS) for 30 min at room temperature.
Samples were loaded on an 8% polyacrylamide/SDS gel.
RESULTS
Cloning of the Murine bek cDNA Encoding a FGF Receptor. The mouse BEK protein was originally identified as a tyrosine kinase in an expression cloning system using antiphosphotyrosine antibodies to screen a liver cDNA library (6) . The partial sequence of BEK was 91% similar to the intracellular catalytic domain ofthe chicken and human FLG FGF receptor (2, 3). We used an 800-bp EcoRI fragment of bek as a probe to isolate a full-length bek cDNA. Two clones that had a 240-bp extension in the 5' direction were isolated and the 240-bp EcoRI fragment (corresponding to amino acids 399-475 in Fig. 1 ) was used to screen several cDNA libraries.
A mouse brain cDNA library yielded a 2-kb EcoRI fragment that overlapped perfectly with the entire probe and encoded the amino terminus of the BEK protein.
The complete deduced protein sequence of BEK is shown in Fig. 1 . Based on the homology to the FLG sequence, the initiator methionine is located at position 607 of the cDNA and is followed by a stretch of 20 (Fig. 2) (Fig. 3) . The Kd was equal to that for our previously described CHO clone 3-4, a CHO line expressing a similar number of two-immunoglobulin-domain FLG receptors with a Kd of 17 pM for bFGF (5) (Fig. 3) .
To determine the relative affinities of bFGF, K-FGF, and aFGF for the BEK receptor, competition curves were generated by measuring the ability of the unlabeled ligands to displace labeled K-FGF. We had previously shown that about 15 times more K-FGF than bFGF is needed to com- Fig. 4 show that on CHO bek 3.7-5 cells, K-FGF is as competent as bFGF or aFGF at displacing the 125I-K-FGF. Similar results were obtained in the reverse experiment using 125I-bFGF (data not shown).
In similar experiments we determined the ability of two other members of the FGF family, FGF-5 and KGF, to displace 125I-bFGF binding from clone CHO 3-4 (FLGexpressing) cells and clone CHO bek 3.7-5 (BEK-expressing) cells. The mitogenic activity of FGF-5 was tested on NIH 3T3 and BALB 3T3 cells to ensure that there was no loss ofactivity ofthe growth factor. The mitogenic activity of KGF was tested on human cervical epithelial cells 183ATLL1 and 183BTLLI. Neither KGF nor FGF-5 can displace 125I-bFGF from CHO 3-4 (FLG) cells (Fig. SA) . On CHO bek 3.7-5 cells, KGF and FGF-5 are unable to displace the labeled bFGF (Fig. SB) displace, at best, 15% of the labeled ligand, indicating an affinity at least 100-fold lower than that of bFGF.
Receptor Activation. To ensure that our cDNA clone encoded a functional receptor, we analyzed ligand-dependent receptor tyrosine phosphorylation in CHO bek 3.7-5 cells. Clone CHO bek 3.7-5 and CHO parental cells stimulated with bFGF and K-FGF were extracted and tested by Western analysis with antiphosphotyrosine antibodies. A band of -140 kDa was seen in BEK clones treated with bFGF and K-FGF at 10 ng/ml but not in those treated with plateletderived growth factor or in untreated cells (data not shown). Thus FGF stimulation of CHO cells expressing the FGF bek receptor leads to the phosphorylation of a protein whose molecular mass corresponds to the receptor that is crosslinked to 125I-bFGF and 125I-K-FGF. The CHO bek 3.7-5 cells also show an increase in the rate of DNA synthesis in response to K-FGF or bFGF in a similar fashion to CHO 3-4 (fig) cells (data not shown) . Additionally, CHO bek 3.7-5 cells exhibit an increase in cell number in response to bFGF and K-FGF at 10 ng/ml in defined medium (data not shown). Although the response is weak, with a cell doubling time up to 40 hr, it is reproducible. The addition of heparin at 10 ,ug/ml to the growth assay made no noticeable difference in the growth curves.
bek Expression in Transfected 32D Cells. The bek cDNA was cloned into the pZip-NeoSV(X)1 vector (23) and introduced into 32D cells. The 32D cells are murine myeloid cells that are negative for bek mRNA by Northern analysis and express no detectable FGF receptors as determined by their inability to bind 1251-bFGF (unpublished observations). These cells are dependent on IL-3 for their proliferation and survival (20) . Clones expressing bek mRNA were tested for their ability to bind 125I-bFGF. Two clones, 32D bek B3 and 32D bek B5, expressed about 3000 receptors per cell (data not shown) and were used for further studies.
32D cells grow extremely poorly when the IL-3 concentration is reduced to about 10% of the optimal concentration for growth, and FGFs with or without heparin are not mitogenic (see Fig. 7 and data not shown). When we tested the ability of BEK-expressing 32D cells to grow in the presence of bFGF or K-FGF in lowered IL-3 conditions, no concentrations (1 ,ug/ml) ofthe growth factors. However, the addition of heparin (50 ,ug/ml) made a dramatic difference and the cells grew in the presence of K-FGF (50 ng/ml) plus heparin as readily as in the presence of 10 units of IL-3 per ml (Fig. 6) . A similar effect was seen in the presence ofbFGF plus heparin, although the growth was somewhat slower than in the presence of 10 units of IL-3 per ml (Fig. 6) . We have been unable to sustain prolonged growth of these cells with FGFs and heparin in the complete absence of IL-3. The reasons for this situation are not clear but could result from the existence of a specific IL-3 signal transduction pathway that is necessary for cell survival.
To determine whether the heparin-dependent growth ofthe 32D bek cells was due to heparin-dependent binding of the ligand to the BEK receptor, we performed crosslinking experiments. 1251-bFGF was crosslinked to 32D bek B3 cells in the presence and absence of heparin. A crosslinked band of =160 kDa corresponding to the size of the ligand-receptor complex was seen in the presence ofheparin. Although a faint band was visible in the absence of heparin, this complex was dramatically increased upon addition of heparin and was competively inhibited by excess unlabeled bFGF (Fig. 7) . This band was absent in 32D parental cells that were similarly treated (data not shown). 32D cells expressing the FLG receptor showed identical results-i.e., they only grew in the presence of FGFs and heparin-and the binding of iodinated bFGF was almost completely heparin dependent (data not shown). We did not detect any difference in the growth responses of 32D fig and 32D bek cells to K-FGF. This result is somewhat surprising given the lower affinity K-FGF has for the FLG receptor. However, FLG-expressing CHO cells also do not differ in their mitogenic response to K-FGF or bFGF in spite of the difference in affinity for the two growth factors (5) .
DISCUSSION
We have demonstrated that the murine BEK receptor expressed in CHO cells is activated by three growth factors of the FGF family, bFGF, aFGF, and K-FGF, whereas it does not bind FGF-5 or KGF to any appreciable extent. This last result is not surprising in the case of KGF, since a distinct receptor has been identified for KGF from keratinocytes that does not bind bFGF (17) . In addition, KGF is known to act specifically on epithelial cells and to have no effect on fibroblast-like NIH 3T3 cells (26) (Fig. 7) . The significance of this low-level binding, which is competitively inhibited by unlabeled bFGF, is unclear, given the strict growth dependence ofthese cells on added heparin. It may be due to other low-affinity receptors present on 32D cells that can partially substitute for the HSPGs and allow a weak interaction between bFGF and the BEK receptor. Alternatively, it is possible that FGFs can bind the BEK receptor with low efficiency even without the conformational changes induced by heparin or HSPGs but that this type of ligandreceptor interaction is unstable. In any case, binding in the absence of heparin is insufficient to activate the BEK mitogenic response in hEK-expressing 32D cells. Although the precise nature of the interaction between these three species remains to be elucidated, it is evident that the biological effects of the FGFs may be regulated at several levels-by the presence of the growth factor, its affinity for the type of tyrosine kinase receptor, and its interaction with the HSPG components that are required to present the growth factor to its receptors.
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